NSCLC predictive biomarkerAbout 6 to 7 percent of non-small cell lung cancer patients have the rearrangementThe prevalence of the EML4-ALK fusion oncogene is higher among lung adenocarcinomas, in non or light smokers and in EGFR, KRAS-negative cases.